Chronic Obstructive Pulmonary Disease in the Older Patient

Clinics in Chest Medicine

Volumn 28, Issue 4, 2007, Pages 703-715

  Nazir, Shoab A ^a,b   Al Hamed, Mohammad M ^a   Erbland, Marcia L ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; METHYLXANTHINE; PLACEBO; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE;

AIRWAY OBSTRUCTION; ANXIETY; CAREGIVER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEPRESSION; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNIZATION; METERED DOSE INHALER; MORBIDITY; MORTALITY; NUTRITION; PALLIATIVE THERAPY; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY OF LIFE; REVIEW; RISK FACTOR; SMOKING CESSATION; TERMINAL CARE;

AGED; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; HUMANS; OXYGEN INHALATION THERAPY; PALLIATIVE CARE; PREVALENCE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 35549000532     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2007.07.003     Document Type: Review

References (190)

1. Snider G.L. Nosology for our day: its application to chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167 5 (2003) 678-683
2. Pauwels R.A., Buist A.S., Calverley P.M., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163 5 (2001) 1256-1276
3. Lopez A.D., Shibuya K., Rao C., et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 27 2 (2006) 397-412
4. Blanc P.D., and Balmes J.R. Epidemiology and costs of COPD. Eur Respir J 28 6 (2006) 1290
5. Murray C.J., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349 9064 (1997) 1498-1504
6. Hurd S.S. International efforts directed at attacking the problem of COPD. Chest 117 5 Suppl 2 (2000) 336S-338S
7. Mannino D.M. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 121 5 Suppl (2002) 121S-126S
8. Miller J.D., Foster T., Boulanger L., et al. Direct costs of COPD in the US, an analysis of Medical Expenditure Panel Survey (MEPS) data. COPD 2 3 (2005) 311-318
9. Mapel D.W., Hurley J.S., Frost F.J., et al. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med 160 17 (2000) 2653-2658
10. Garrett N., and Martini E.M. The boomers are coming: a total cost of care model of the impact of population aging on the cost of chronic conditions in the United States. Dis Manag 10 2 (2007) 51-60
11. Davis R.M., and Novotny T.E. The epidemiology of cigarette smoking and its impact on chronic obstructive pulmonary disease. Am Rev Respir Dis 140 3 Pt 2 (1989) S82-S84
12. Fletcher C., and Peto R. The natural history of chronic airflow obstruction. Br Med J 1 6077 (1977) 1645-1648
13. Burrows B., Knudson R.J., Cline M.G., et al. Quantitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis 115 2 (1977) 195-205
14. Cigarette smoking among adults-United States, 2004. MMWR Morb Mortal Wkly Rep 54 44 (2005) 1121-1124
15. Prevalence of current cigarette smoking among adults and changes in prevalence of current and some day smoking-United States, 1996-2001. MMWR Morb Mortal Wkly Rep 52 14 (2003) 303-304 306-7
16. Eriksson S. Pulmonary emphysema and alpha1-antitrypsin deficiency. Acta Med Scand 175 (1964) 197-205
17. Tobin M.J., Cook P.J., and Hutchison D.C. Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association. Br J Dis Chest 77 1 (1983) 14-27
18. Zock J.P., Sunyer J., Kogevinas M., et al. Occupation, chronic bronchitis, and lung function in young adults. An international study. Am J Respir Crit Care Med 163 7 (2001) 1572-1577
19. Tashkin D.P., Clark V.A., Coulson A.H., et al. The UCLA population studies of chronic obstructive respiratory disease. VIII. Effects of smoking cessation on lung function: a prospective study of a free-living population. Am Rev Respir Dis 130 5 (1984) 707-715
20. Perez-Padilla R., Regalado J., Vedal S., et al. Exposure to biomass smoke and chronic airway disease in Mexican women. A case-control study. Am J Respir Crit Care Med 154 3 Pt 1 (1996) 701-706
21. Dennis R.J., Maldonado D., Norman S., et al. Woodsmoke exposure and risk for obstructive airways disease among women. Chest 109 1 (1996) 115-119
22. Vestbo J., Prescott E., and Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 153 5 (1996) 1530-1535
23. Tashkin D.P., Altose M.D., Connett J.E., et al. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med 153 6 Pt 1 (1996) 1802-1811
24. Burrows B. Airways obstructive diseases: pathogenetic mechanisms and natural histories of the disorders. Med Clin North Am 74 3 (1990) 547-559
25. Connett J.E., Murray R.P., Buist A.S., et al. Changes in smoking status affect women more than men: results of the Lung Health Study. Am J Epidemiol 157 11 (2003) 973-979
26. Chen Y., Horne S.L., and Dosman J.A. Increased susceptibility to lung dysfunction in female smokers. Am Rev Respir Dis 143 6 (1991) 1224-1230
27. de Torres J.P., Campo A., Casanova C., et al. Gender and chronic obstructive pulmonary disease in high-risk smokers. Respiration 73 3 (2006) 306-310
28. De Filippi F., Tana F., Vanzati S., et al. Study of respiratory function in the elderly with different nutritional and cognitive status and functional ability assessed by plethysmographic and spirometric parameters. Arch Gerontol Geriatr 37 1 (2003) 33-43
29. Pezzoli L., Giardini G., Consonni S., et al. Quality of spirometric performance in older people. Age Ageing 32 1 (2003) 43-46
30. Sherman C.B., Kern D., Richardson E.R., et al. Cognitive function and spirometry performance in the elderly. Am Rev Respir Dis 148 1 (1993) 123-126
31. Celli B.R., and MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 6 (2004) 932-946
32. Pellegrino R., Viegi G., Brusasco V., et al. Interpretative strategies for lung function tests. Eur Respir J 26 5 (2005) 948-968
33. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis 144 5 (1991) 1202-1218
34. Crapo R.O., Morris A.H., and Gardner R.M. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 123 6 (1981) 659-664
35. Hankinson J.L., Odencrantz J.R., and Fedan K.B. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 159 1 (1999) 179-187
36. Knudson R.J., Lebowitz M.D., Holberg C.J., et al. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 127 6 (1983) 725-734
37. Burrows B., Lebowitz M.D., Camilli A.E., et al. Longitudinal changes in forced expiratory volume in one second in adults. Methodologic considerations and findings in healthy nonsmokers. Am Rev Respir Dis 133 6 (1986) 974-980
38. Gelb A.F., and Zamel N. Effect of aging on lung mechanics in healthy nonsmokers. Chest 68 4 (1975) 538-541
39. Celli B.R., Halbert R.J., Isonaka S., et al. Population impact of different definitions of airway obstruction. Eur Respir J 22 2 (2003) 268-273
40. Hardie J.A., Buist A.S., Vollmer W.M., et al. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 20 5 (2002) 1117-1122
41. Medbo A., and Melbye H. Lung function testing in the elderly-can we still use FEV(1)/FVC<70% as a criterion of COPD?. Respir Med 10 6 (2007) 1097-1105
42. Hansen J.E., Sun X.G., and Wasserman K. Spirometric criteria for airway obstruction: use percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. Chest 131 2 (2007) 349-355
43. Mannino D.M., Sonia Buist A., and Vollmer W.M. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function?. Thorax 62 3 (2007) 237-241
44. Lindberg A., Bjerg-Backlund A., Ronmark E., et al. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 100 2 (2006) 264-272
45. Lundback B., Gulsvik A., Albers M., et al. Epidemiological aspects and early detection of chronic obstructive airway diseases in the elderly. Eur Respir J Suppl 40 (2003) 3s-9s
46. Lindstrom M., Jonsson E., Larsson K., et al. Underdiagnosis of chronic obstructive pulmonary disease in Northern Sweden. Int J Tuberc Lung Dis 6 1 (2002) 76-84
47. Sciurba F.C. Physiologic similarities and differences between COPD and asthma. Chest 126 2 Suppl (2004) 117S-124S [discussion: 159S-161S]
48. Bellia V., Battaglia S., Catalano F., et al. Aging and disability affect misdiagnosis of COPD in elderly asthmatics: the SARA study. Chest 123 4 (2003) 1066-1072
49. Halbert R.J., Isonaka S., George D., et al. Interpreting COPD prevalence estimates: what is the true burden of disease?. Chest 123 5 (2003) 1684-1692
50. Mannino D.M., Gagnon R.C., Petty T.L., et al. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 160 11 (2000) 1683-1689
51. Isoaho R., Puolijoki H., Huhti E., et al. Prevalence of chronic obstructive pulmonary disease in elderly Finns. Respir Med 88 8 (1994) 571-580
52. Burchfiel C.M., Marcus E.B., Curb J.D., et al. Effects of smoking and smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med 151 6 (1995) 1778-1785
53. Pelkonen M., Notkola I.L., Tukiainen H., et al. Smoking cessation, decline in pulmonary function and total mortality: a 30-year follow up study among the Finnish cohorts of the Seven Countries Study. Thorax 56 9 (2001) 703-707
54. Higgins M.W., Enright P.L., Kronmal R.A., et al. Smoking and lung function in elderly men and women. The Cardiovascular Health Study. JAMA 269 21 (1993) 2741-2748
55. Vollset S.E., Tverdal A., and Gjessing H.K. Smoking and deaths between 40 and 70 years of age in women and men. Ann Intern Med 144 6 (2006) 381-389
56. Taylor Jr. D.H., Hasselblad V., Henley S.J., et al. Benefits of smoking cessation for longevity. Am J Public Health 92 6 (2002) 990-996
57. Anthonisen N.R., Skeans M.A., Wise R.A., et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142 4 (2005) 233-239
58. Tait R.J., Hulse G.K., Waterreus A., et al. Effectiveness of a smoking cessation intervention in older adults. Addiction 102 1 (2007) 148-155
59. Hurt R.D., Sachs D.P., Glover E.D., et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337 17 (1997) 1195-1202
60. Gonzales D., Rennard S.I., Nides M., et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296 1 (2006) 47-55
61. Jorenby D.E., Hays J.T., Rigotti N.A., et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296 1 (2006) 56-63
62. Maguire C.P., Ryan J., Kelly A., et al. Do patient age and medical condition influence medical advice to stop smoking?. Age Ageing 29 3 (2000) 264-266
63. Anthonisen N.R., Connett J.E., Kiley J.P., et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 272 19 (1994) 1497-1505
64. Anthonisen N.R., Connett J.E., Enright P.L., et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 166 3 (2002) 333-339
65. Belman M.J., Botnick W.C., and Shin J.W. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153 3 (1996) 967-975
66. O'Donnell D.E., Lam M., and Webb K.A. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160 2 (1999) 542-549
67. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest 105 5 (1994) 1411-1419
68. Appleton S., Jones T., Poole P., et al. Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2 (2006) CD001387
69. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group. Chest 112 6 (1997) 1514-1521
70. Appleton S., Poole P., Smith B., et al. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev 3 (2006) CD001104
71. Jones P.W., and Bosh T.K. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 155 4 (1997) 1283-1289
72. Dahl R., Greefhorst L.A., Nowak D., et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 5 (2001) 778-784
73. Appleton S., Jones T., Poole P., et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 3 (2006) CD006101
74. ZuWallack R.L., Mahler D.A., Reilly D., et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 119 6 (2001) 1661-1670
75. Casaburi R., Mahler D.A., Jones P.W., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19 2 (2002) 217-224
76. Vincken W., van Noord J.A., Greefhorst A.P., et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 19 2 (2002) 209-216
77. Barr R.G., Bourbeau J., Camargo C.A., et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 61 10 (2006) 854-862
78. Brusasco V., Hodder R., Miravitlles M., et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58 5 (2003) 399-404
79. Donohue J.F., van Noord J.A., Bateman E.D., et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122 1 (2002) 47-55
80. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 343 26 (2000) 1902-1909
81. Burge P.S., Calverley P.M., Jones P.W., et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320 7245 (2000) 1297-1303
82. Pauwels R.A., Lofdahl C.G., Laitinen L.A., et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on chronic obstructive pulmonary disease. N Engl J Med 340 25 (1999) 1948-1953
83. Vestbo J., Sorensen T., Lange P., et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353 9167 (1999) 1819-1823
84. Jarad N.A., Wedzicha J.A., Burge P.S., et al. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med 93 3 (1999) 161-166
85. van der Valk P., Monninkhof E., van der Palen J., et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 166 10 (2002) 1358-1363
86. Johnell O., Pauwels R., Lofdahl C.G., et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J 19 6 (2002) 1058-1063
87. Calverley P.M., Anderson J.A., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 8 (2007) 775-789
88. Calverley P., Pauwels R., Vestbo J., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361 9356 (2003) 449-456
89. Calverley P.M., Boonsawat W., Cseke Z., et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22 6 (2003) 912-919
90. Mahler D.A., Wire P., Horstman D., et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166 8 (2002) 1084-1091
91. Szafranski W., Cukier A., Ramirez A., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21 1 (2003) 74-81
92. Aaron S.D., Vandemheen K.L., Fergusson D., et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 146 8 (2007) 545-555
93. Diggory P., Fernandez C., Humphrey A., et al. Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 322 7286 (2001) 577-579
94. Jarvis S., Ind P.W., and Shiner R.J. Inhaled therapy in elderly COPD patients; time for re-evaluation?. Age Ageing 36 2 (2007) 213-218
95. Allen S.C. Competence thresholds for the use of inhalers in people with dementia. Age Ageing 26 2 (1997) 83-86
96. Allen S.C., and Ragab S. Ability to learn inhaler technique in relation to cognitive scores and tests of praxis in old age. Postgrad Med J 78 915 (2002) 37-39
97. Chapman K.R., Love L., and Brubaker H. A comparison of breath-actuated and conventional metered-dose inhaler inhalation techniques in elderly subjects. Chest 104 5 (1993) 1332-1337
98. Ho S.F., O'Mahoney M.S., Steward J.A., et al. Inhaler technique in older people in the community. Age Ageing 33 2 (2004) 185-188
99. Jones V., Fernandez C., and Diggory P. A comparison of large volume spacer, breath-activated and dry powder inhalers in older people. Age Ageing 28 5 (1999) 481-484
100. Dolovich M.B., Ahrens R.C., Hess D.R., et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 127 1 (2005) 335-371
101. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 93 3 (1980) 391-398
102. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1 8222 (1981) 681-686
103. Gorecka D., Gorzelak K., Sliwinski P., et al. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax 52 8 (1997) 674-679
104. Chaouat A., Weitzenblum E., Kessler R., et al. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Eur Respir J 14 5 (1999) 1002-1008
105. Croxton T.L., and Bailey W.C. Long-term oxygen treatment in chronic obstructive pulmonary disease: recommendations for future research: an NHLBI workshop report. Am J Respir Crit Care Med 174 4 (2006) 373-378
106. Pulmonary rehabilitation-1999. American Thoracic Society. Am J Respir Crit Care Med 159 5 Pt 1 (1999) 1666-1682
107. Nici L., Donner C., Wouters E., et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 173 12 (2006) 1390-1413
108. Guell R., Casan P., Belda J., et al. Long-term effects of outpatient rehabilitation of COPD: a randomized trial. Chest 117 4 (2000) 976-983
109. Troosters T., Gosselink R., and Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Am J Med 109 3 (2000) 207-212
110. Paz-Diaz H., Montes de Oca M., Lopez J.M., et al. Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. Am J Phys Med Rehabil 86 1 (2007) 30-36
111. Takigawa N., Tada A., Soda R., et al. Comprehensive pulmonary rehabilitation according to severity of COPD. Respir Med 101 2 (2007) 326-332
112. Wijkstra P.J., Ten Vergert E.M., van Altena R., et al. Long term benefits of rehabilitation at home on quality of life and exercise tolerance in patients with chronic obstructive pulmonary disease. Thorax 50 8 (1995) 824-828
113. Couser Jr. J.I., Guthmann R., Hamadeh M.A., et al. Pulmonary rehabilitation improves exercise capacity in older elderly patients with COPD. Chest 107 3 (1995) 730-734
114. Hak E., van Essen G.A., Buskens E., et al. Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice-based clinical prospective cohort study in Utrecht, The Netherlands. J Epidemiol Community Health 52 2 (1998) 120-125
115. Nichol K.L., Margolis K.L., Wuorenma J., et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 331 12 (1994) 778-784
116. Jackson L.A., Neuzil K.M., Yu O., et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 348 18 (2003) 1747-1755
117. Vila-Corcoles A., Ochoa-Gondar O., Hospital I., et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 43 7 (2006) 860-868
118. Granger R., Walters J., Poole P.J., et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 4 (2006) CD001390
119. Keller H.H. Malnutrition in institutionalized elderly: how and why?. J Am Geriatr Soc 41 11 (1993) 1212-1218
120. Lipski P.S., Torrance A., Kelly P.J., et al. A study of nutritional deficits of long-stay geriatric patients. Age Ageing 22 4 (1993) 244-255
121. Bienia R., Ratcliff S., Barbour G.L., et al. Malnutrition in the hospitalized geriatric patient. J Am Geriatr Soc 30 7 (1982) 433-436
122. Constans T., Bacq Y., Brechot J.F., et al. Protein-energy malnutrition in elderly medical patients. J Am Geriatr Soc 40 3 (1992) 263-268
123. Payette H., Coulombe C., Boutier V., et al. Weight loss and mortality among free-living frail elders: a prospective study. J Gerontol A Biol Sci Med Sci 54 9 (1999) M440-M445
124. Sullivan D.H., Sun S., and Walls R.C. Protein-energy undernutrition among elderly hospitalized patients: a prospective study. JAMA 281 21 (1999) 2013-2019
125. Vandenbergh E., Van de Woestijne K.P., and Gyselen A. Weight changes in the terminal stages of chronic obstructive pulmonary disease. Relation to respiratory function and prognosis. Am Rev Respir Dis 95 4 (1967) 556-566
126. Chailleux E., Laaban J.P., and Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR observatory. Chest 123 5 (2003) 1460-1466
127. Gray-Donald K., Gibbons L., Shapiro S.H., et al. Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153 3 (1996) 961-966
128. Landbo C., Prescott E., Lange P., et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160 6 (1999) 1856-1861
129. Schols A.M., Slangen J., Volovics L., et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157 6 Pt 1 (1998) 1791-1797
130. Marti S., Munoz X., Rios J., et al. Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy. Eur Respir J 27 4 (2006) 689-696
131. Payette H., Boutier V., Coulombe C., et al. Benefits of nutritional supplementation in free-living, frail, undernourished elderly people: a prospective randomized community trial. J Am Diet Assoc 102 8 (2002) 1088-1095
132. Efthimiou J., Fleming J., Gomes C., et al. The effect of supplementary oral nutrition in poorly nourished patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 137 5 (1988) 1075-1082
133. Rogers R.M., Donahoe M., and Costantino J. Physiologic effects of oral supplemental feeding in malnourished patients with chronic obstructive pulmonary disease. A randomized control study. Am Rev Respir Dis 146 6 (1992) 1511-1517
134. Whittaker J.S., Ryan C.F., Buckley P.A., et al. The effects of refeeding on peripheral and respiratory muscle function in malnourished chronic obstructive pulmonary disease patients. Am Rev Respir Dis 142 2 (1990) 283-288
135. Schols A.M., Broekhuizen R., Weling-Scheepers C.A., et al. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 82 1 (2005) 53-59
136. Slinde F., Gronberg A., Engstrom C.P., et al. Body composition by bioelectrical impedance predicts mortality in chronic obstructive pulmonary disease patients. Respir Med 99 8 (2005) 1004-1009
137. Vestbo J., Prescott E., Almdal T., et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 173 1 (2006) 79-83
138. Hopkinson N.S., Tennant R.C., Dayer M.J., et al. A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive pulmonary disease. Respir Res 8 (2007) 25-32
139. Creutzberg E.C., Wouters E.F., Mostert R., et al. A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest 124 5 (2003) 1733-1742
140. Schols A.M., Soeters P.B., Mostert R., et al. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med 152 4 Pt 1 (1995) 1268-1274
141. Liu H., Bravata D.M., Olkin I., et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 146 2 (2007) 104-115
142. Ferrer M., Alonso J., Morera J., et al. Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med 127 12 (1997) 1072-1079
143. Stewart A.L., Greenfield S., Hays R.D., et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 262 7 (1989) 907-913
144. Schellevis F.G., van der Velden J., van de Lisdonk E., et al. Comorbidity of chronic diseases in general practice. J Clin Epidemiol 46 5 (1993) 469-473
145. Fuso L., Incalzi R.A., Pistelli R., et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 98 3 (1995) 272-277
146. Antonelli Incalzi R., Fuso L., De Rosa M., et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 10 12 (1997) 2794-2800
147. Yeo J., Karimova G., and Bansal S. Co-morbidity in older patients with COPD-its impact on health service utilisation and quality of life, a community study. Age Ageing 35 1 (2006) 33-37
148. Patil S.P., Krishnan J.A., Lechtzin N., et al. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 163 10 (2003) 1180-1186
149. Zielinski J., MacNee W., Wedzicha J., et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 52 1 (1997) 43-47
150. Carson J.L., Terrin M.L., Duff A., et al. Pulmonary embolism and mortality in patients with COPD. Chest 110 5 (1996) 1212-1219
151. Kim H.F., Kunik M.E., Molinari V.A., et al. Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics 41 6 (2000) 465-471
152. Bosley C.M., Corden Z.M., Rees P.J., et al. Psychological factors associated with use of home nebulized therapy for COPD. Eur Respir J 9 11 (1996) 2346-2350
153. Light R.W., Merrill E.J., Despars J.A., et al. Prevalence of depression and anxiety in patients with COPD. Relationship to functional capacity. Chest 87 1 (1985) 35-38
154. Yohannes A.M., Roomi J., Baldwin R.C., et al. Depression in elderly outpatients with disabling chronic obstructive pulmonary disease. Age Ageing 27 2 (1998) 155-160
155. Yohannes A.M., Baldwin R.C., and Connolly M.J. Depression and anxiety in elderly outpatients with chronic obstructive pulmonary disease: prevalence, and validation of the BASDEC screening questionnaire. Int J Geriatr Psychiatry 15 12 (2000) 1090-1096
156. Incalzi R.A., Chiappini F., Fuso L., et al. Predicting cognitive decline in patients with hypoxaemic COPD. Respir Med 92 3 (1998) 527-533
157. Koenig H.G., George L.K., Peterson B.L., et al. Depression in medically ill hospitalized older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemes. Am J Psychiatry 154 10 (1997) 1376-1383
158. McCusker J., Cole M., Dufouil C., et al. The prevalence and correlates of major and minor depression in older medical inpatients. J Am Geriatr Soc 53 8 (2005) 1344-1353
159. Engstrom C.P., Persson L.O., Larsson S., et al. Functional status and well being in chronic obstructive pulmonary disease with regard to clinical parameters and smoking: a descriptive and comparative study. Thorax 51 8 (1996) 825-830
160. Yellowlees P.M., Alpers J.H., Bowden J.J., et al. Psychiatric morbidity in patients with chronic airflow obstruction. Med J Aust 146 6 (1987) 305-307
161. Cully J.A., Graham D.P., Stanley M.A., et al. Quality of life in patients with chronic obstructive pulmonary disease and comorbid anxiety or depression. Psychosomatics 47 4 (2006) 312-319
162. Argyropoulou P., Patakas D., Koukou A., et al. Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiration 60 4 (1993) 216-220
163. Borson S., McDonald G.J., Gayle T., et al. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics 33 2 (1992) 190-201
164. Eiser N., Harte R., Spiros K., et al. Effect of treating depression on quality-of-life and exercise tolerance in severe COPD. COPD 2 2 (2005) 233-241
165. Yohannes A.M., Connolly M.J., and Baldwin R.C. A feasibility study of antidepressant drug therapy in depressed elderly patients with chronic obstructive pulmonary disease. Int J Geriatr Psychiatry 16 5 (2001) 451-454
166. Sirey J.A., Raue P.J., and Alexopoulos G.S. An intervention to improve depression care in older adults with COPD. Int J Geriatr Psychiatry 22 2 (2007) 154-159
167. Prigatano G.P., Wright E.C., and Levin D. Quality of life and its predictors in patients with mild hypoxemia and chronic obstructive pulmonary disease. Arch Intern Med 144 8 (1984) 1613-1619
168. McSweeny A.J., Grant I., Heaton R.K., et al. Life quality of patients with chronic obstructive pulmonary disease. Arch Intern Med 142 3 (1982) 473-478
169. Peruzza S., Sergi G., Vianello A., et al. Chronic obstructive pulmonary disease (COPD) in elderly subjects: impact on functional status and quality of life. Respir Med 97 6 (2003) 612-617
170. Tsukino M., Nishimura K., Ikeda A., et al. Physiologic factors that determine the health-related quality of life in patients with COPD. Chest 110 4 (1996) 896-903
171. Jones P.W. Issues concerning health-related quality of life in COPD. Chest 107 5 Suppl (1995) 187S-193S
172. Jones P.W., Quirk F.H., and Baveystock C.M. The St George's respiratory questionnaire. Respir Med 85 Suppl B (1991) 25-31 [discussion: 27-33]
173. Okubadejo A.A., Jones P.W., and Wedzicha J.A. Quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia. Thorax 51 1 (1996) 44-47
174. Wang Q., and Bourbeau J. Outcomes and health-related quality of life following hospitalization for an acute exacerbation of COPD. Respirology 10 3 (2005) 334-340
175. Anthonisen N.R., Wright E.C., and Hodgkin J.E. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 133 1 (1986) 14-20
176. Kanner R.E., Renzetti Jr. A.D., Stanish W.M., et al. Predictors of survival in subjects with chronic airflow limitation. Am J Med 74 2 (1983) 249-255
177. Postma D.S., Gimeno F., van der Weele L.T., et al. Assessment of ventilatory variables in survival prediction of patients with chronic airflow obstruction: the importance of reversibility. Eur J Respir Dis 67 5 (1985) 360-368
178. Burrows B., and Earle R.H. Prediction of survival in patients with chronic airway obstruction. Am Rev Respir Dis 99 6 (1969) 865-871
179. Yohannes A.M., Baldwin R.C., and Connolly M. Mortality predictors in disabling chronic obstructive pulmonary disease in old age. Age Ageing 31 2 (2002) 137-140
180. Soler-Cataluna J.J., Martinez-Garcia M.A., Roman Sanchez P., et al. Severe acute exacerbations and mortality in patients with chronic
181. Seneff M.G., Wagner D.P., Wagner R.P., et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 274 23 (1995) 1852-1857
182. Almagro P., Calbo E., Ochoa de Echaguen A., et al. Mortality after hospitalization for COPD. Chest 121 5 (2002) 1441-1448
183. Claessens M.T., Lynn J., Zhong Z., et al. Dying with lung cancer or chronic obstructive pulmonary disease: insights from SUPPORT. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. J Am Geriatr Soc 48 5 Suppl (2000) S146-S153
184. Lynn J., Ely E.W., Zhong Z., et al. Living and dying with chronic obstructive pulmonary disease. J Am Geriatr Soc 48 5 Suppl (2000) S91-S100
185. Elkington H., White P., Addington-Hall J., et al. The last year of life of COPD: a qualitative study of symptoms and services. Respir Med 98 5 (2004) 439-445
186. Gore J.M., Brophy C.J., and Greenstone M.A. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax 55 12 (2000) 1000-1006
187. Mast K.R., Salama M., Silverman G.K., et al. End-of-life content in treatment guidelines for life-limiting diseases. J Palliat Med 7 6 (2004) 754-773
188. Shee C.D. Palliation in chronic respiratory disease. Palliat Med 9 1 (1995) 3-12
189. Seamark D.A., Blake S.D., Seamark C.J., et al. Living with severe chronic obstructive pulmonary disease (COPD): perceptions of patients and their carers. An interpretative phenomenological analysis. Palliat Med 18 7 (2004) 619-625
190. Kara M., and Mirici A. Loneliness, depression, and social support of Turkish patients with chronic obstructive pulmonary disease and their spouses. J Nurs Scholarsh 36 4 (2004) 331-336